Compare Novartis AG (NVS) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs S&P Global Inc — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while S&P Global Inc trades at $408.97 (market cap $121.15B). The key difference: Novartis AG is far larger — about 2.5× S&P Global Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | SPGI | |
|---|---|---|
Market Cap | $298.18B | $121.15B |
Sector | Health | Financials |
52-Week High | $168.62 | $534.79 |
52-Week Low | $119.31 | $370.42 |
Enterprise Value | $339.50B | $132.63B |
Dividend Yield | 3.02% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
S&P Global (SPGI) trades at $408.19, up 0.73% today, with strong analyst support (85.7% buy ratings) and a $523.20 consensus price target suggesting 28% upside. Recent Q2 2026 earnings beat expectations at $4.83 EPS, continuing a trend of profitability with 30.54% net margins. Technical indicators show bearish momentum near key support at $404, while fundamentals reveal robust revenue growth to $15.34B in 2025 and expanding cash flow.
The stock presents a compelling long-term opportunity given its dominant market position in ratings and indices, though near-term technical weakness and competitive pressures pose risks. Earnings consistency and strategic initiatives in AI and data analytics support upside potential, but investors should monitor debt levels increasing to 23.29% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
